The TL1A–DR3 signaling pathway plays a central role in the development and progression of Crohn’s disease (CD), a chronic inflammatory condition of the intestines. Research has shown that TL1A activates DR3, a receptor that drives proinflammatory immune responses, particularly through T helper 9 (Th9) cells.
The TL1A–DR3 signaling pathway plays a central role in the development and progression of Crohn’s disease (CD), a chronic inflammatory condition of the intestines. Research has shown that TL1A activates DR3, a receptor that drives proinflammatory immune responses, particularly through T helper 9 (Th9) cells. These Th9 cells produce interleukin-9 (IL-9), a key inflammatory cytokine that contributes to intestinal damage and inflammation in CD.
Using experimental models, researchers studied mice with Crohn’s-like ileitis (SAMP1/YitFc) and DR3-deficient mice to understand the role of this pathway. DR3-deficient mice exhibited reduced intestinal inflammation, lower IL-9 levels, and improved histology, highlighting DR3’s role in sustaining immune hyperactivation. Neutralizing IL-9 with antibodies significantly alleviated inflammation and tissue damage, confirming IL-9’s importance in disease progression.
Under Th9-polarizing conditions, DR3 was essential for inducing IL-9 production. Wild-type Th9 cells (Th9^WT) showed high levels of IL-9 and other inflammatory cytokines, while DR3-deficient Th9 cells (Th9^KO) shifted toward an anti-inflammatory phenotype, producing more IL-10. Molecular studies revealed that DR3 deficiency suppressed proinflammatory genes and pathways, including JAK/STAT and PI3K–AKT, while enhancing regulatory markers like Foxp3 and IL-10.
Human studies validated these findings, showing upregulation of Th9-related genes in Crohn’s disease patients, linking the TL1A–DR3–IL-9 axis to human intestinal inflammation. Therapeutically, targeting DR3 or IL-9 could provide a novel approach to treat Crohn’s disease by reducing Th9-driven inflammation and restoring immune balance.
Introduction: Intrahepatic cholangiocarcinoma (ICC) is an aggressive primary liver cancer with poor prognosis and limited treatment options. While ICC has traditionally been considered a malignancy of biliary epithelial cells, increasing evidence suggests that hepatocytes can...
Introduction: Liver fibrosis is the key determinant of long-term outcomes in metabolic dysfunction-associated steatohepatitis (MASH). Activated hepatic stellate cells (HSCs) drive fibrogenesis, but effective antifibrotic therapies remain unavailable. This study investigated whether blocking the succinate–GPR91...
Introduction: The progression from metabolic dysfunction-associated fatty liver (MAFL) to metabolic dysfunction-associated steatohepatitis (MASH) is driven by complex interactions between hepatocytes and immune cells. This study identifies a novel spatial mechanism in the periportal (PP)...
Introduction: Cardiovascular–Kidney–Metabolic (CKM) syndrome recognizes the close interaction between obesity, type 2 diabetes, chronic kidney disease, and cardiovascular disease. This review highlights the emerging role of the gut microbiome, particularly butyrate-producing bacteria, as a central...
• Small intestinal adenocarcinoma (SIA) is a rare gastrointestinal cancer with limited disease-specific prognostic biomarkers and generally poor outcomes. • This nationwide Dutch population-based study evaluated whether three routinely available immunohistochemical markers—CK7, CK20, and CDX2—have...
Introduction: Metabolic dysfunction–associated steatotic liver disease (MASLD) is closely linked to insulin resistance and type 2 diabetes, with the liver traditionally viewed as a key regulator of blood glucose through hepatic glucose production. However, emerging...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.